A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Exclusion Criteria

• •Participant has not recovered (i.e., to Grade less than or equal to \[≤1\] or to baseline) from prior chemotherapy-induced AEs.
• •Participant is currently participating in a treatment study or has participated in a study of any investigational agent within 4 weeks of the first dose of treatment.
• •Participant has symptomatic uncontrolled brain or leptomeningeal metastases.
• •Participant has a known additional malignancy that progressed or required active treatment within the last 2 years
• •Participant has a known history of Myelodysplastic syndrome (MDS) or Acute myeloid leukemia (AML).
• •Participant has uncontrolled hypertension with sustained systolic blood pressure (BP) \>140 millimetres of mercury (mmHg) or diastolic BP \>90 mmHg.